Non-invasive blood biomarkers to detect colorectal cancer and high-grade adenomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll three groups: patients with diagnosed colorectal cancer undergoing surgery, people with negative colonoscopy results, and people found to have high-grade adenomas. Participants will give medical history and provide blood at enrollment and at a follow-up visit, while leftover surgical tissue will be collected when available. Investigators will analyze serum and tissue for nucleic acids, proteins, and other macromolecules and combine signals to create a predictive score for colorectal cancer development. No experimental treatments are given; samples are collected alongside routine clinical care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* AIM 1: Patients undergoing surgery at the U.O.C. of Surgery, with a diagnosis of CRC.
* AIM 2: Subjects without colon disease.
* AIM 3: Subjects with adenoma and high-grade dysplasia.

Exclusion Criteria:

* Subject with any other pathology not included in the inclusion criteria.

Where it's running

• Biobank Core Facility
  Castellana Grotte, Italy Recruiting

Study contacts

• Study coordinator: Pasqua Letizia Pesole, Biologist
• Email: letizia.pesole@irccsdebellis.it
• Phone: +390804994365

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stool-based gene methylation test for early colorectal cancer and adenoma detection

  This project will try a stool-based DNA methylation test to see if it can detect colorectal cancer and adenomas in people aged 40 and older.

  Recruiting Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07033156

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• HDM2017 combination therapy in advanced colorectal cancer

  A small and mid-size study tests HDM2017 with standard chemotherapy and targeted drugs to see if it’s safe and may help people with unresectable or metastatic colorectal cancer.

  Recruiting Phase 1/2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07805551

• Retlirafusp alfa with bevacizumab and chemotherapy (with or without short radiotherapy) for colorectal cancer liver metastases

  This study tests whether adding retlirafusp alfa to bevacizumab and chemotherapy, with or without short-course radiotherapy, can help patients with advanced colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07728019

• SHR-1701 with short-course radiotherapy and CAPOX before surgery for locally advanced rectal cancer

  This will test whether adding the drug SHR-1701 to short-course radiotherapy plus CAPOX before surgery helps people with locally advanced rectal cancer.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07478731

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.